Abstract
Nitric oxide (NO) plays an important role in various physiological processes. Nitric oxide is synthesized by a family of NO synthases (NOS). Of the three isoforms of NOS, inducible NOS (INOS) is closely linked to inflammatory and autoimmune diseases. The suppression of excess NO production in participating cells may be helpful in improving disease status. This review describes a new mechanism of inhibition of NO production by targeting iNOS dimerization. Nitric oxide synthase isoforms are only active as nomodimers. The oxygenase domains of two NOS monomers interact to form the dimer. Certain imidazole derivatives, including PPA250, inhibit this step and suppress NO production. Crystallographic studies have shown that an INOS dimerization inhibitor blocks dimer formation by coordinating the heme in the monomer. Oral administration of PPA250 suppressed the development of arthritis after clinical symptoms had appeared in animal models. PPA250 also decreased the serum concentration of NO in mice treated with lipopolysaccharide (LPS). These results indicate that inhibitors of iNOS homodimerization could be useful therapeutic agents for rheumatoid arthritis, septic shock and other diseases in which NO is involved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
